Winfield Associates’s PDL BioPharma, Inc. PDLI Stock Holding History

Winfield Associates’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-300	Closed	-$1K	–	802
2017 Q4	$1K	Hold	300	–	–	﹤0.01%	825
2017 Q3	$1K	Hold	300	–	–	﹤0.01%	774
2017 Q2	$1K	Hold	300	–	–	﹤0.01%	856
2017 Q1	$1K	Hold	300	–	–	﹤0.01%	738
2016 Q4	$1K	Hold	300	–	–	﹤0.01%	714
2016 Q3	$1K	Hold	300	–	–	﹤0.01%	676
2016 Q2	$1K	Hold	300	–	–	﹤0.01%	690
2016 Q1	$1K	Hold	300	–	–	﹤0.01%	676
2015 Q4	$1K	Hold	300	–	–	﹤0.01%	303
2015 Q3	$2K	Hold	300	–	–	﹤0.01%	295
2015 Q2	$2K	Hold	300	–	–	﹤0.01%	279
2015 Q1	$2K	Hold	300	–	–	﹤0.01%	284
2014 Q4	$2K	Hold	300	–	–	﹤0.01%	292
2014 Q3	$2K	Sell	300 -200	-40%	-$1.86K	﹤0.01%	277
2014 Q2	$4K	Hold	500	–	–	﹤0.01%	286
2014 Q1	$4K	Hold	500	–	–	﹤0.01%	274
2013 Q4	$4K	Buy	+500	New	+$4.21K	﹤0.01%	264

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Winfield Associates's PDLI Position: Q1 2018 in Review

Winfield Associates sold out of PDL BioPharma, Inc. (PDLI) in Q1 2018, closing a stake of 300 shares — an estimated $1K sold.

Winfield Associates first reported a position in PDLI in Q4 2013 and held it in 17 quarters. The position peaked at $4K in Q2 2014. 176 funds tracked by Wall St. Rank hold PDLI as of Q1 2018.

Winfield Associates reported no remaining PDL BioPharma, Inc. position as of Q1 2018 after selling out during the quarter.
Winfield Associates sold 300 PDL BioPharma, Inc. shares in Q1 2018, an estimated $1K.
Winfield Associates first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 17 quarters.
Winfield Associates's PDL BioPharma, Inc. position peaked at $4K in Q2 2014.
176 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.